AI in Diagnostics Market Outlook 2032: Expansion in Primary Care & Home Diagnostic Tools
AI in Diagnostics Market Outlook 2032: Expansion in Primary Care & Home Diagnostic Tools
The AI in diagnostics market is expanding rapidly as healthcare providers adopt advanced artificial intelligence tools to improve accuracy, speed, and efficiency in disease detection. AI systems are being used extensively in radiology, pathology, cardiology, oncology, and neurology to assist with imaging interpretation, predictive analytics, and data-driven diagnosis. Driven by a global shortage of specialists, rising chronic disease cases, and increased funding for AI adoption, this market is projected to grow at impressive rates worldwide. Major players such as Microsoft, NVIDIA, and Google are leading the effort to integrate AI capabilities into clinical workflows. As regulatory frameworks evolve and digital healthcare adoption increases, AI in diagnostics is expected to become a core component of modern medical practice.
According to Fortune Business Insights, the global AI in diagnostics market size was valued at USD 5.15 billion in 2024. The market is projected to grow from USD 7.03 billion in 2025 to USD 96.52 billion by 2032, exhibiting a CAGR of 45.4% during the forecast period. North America dominated the AI in diagnostics market with a market share of 51.46% in 2024.
Amazon.com, Inc. (U.S.)
Microsoft Corporation (U.S.)
NVIDIA Corporation (U.S.)
Google (U.S.)
Siemens Healthcare Private Limited (Germany)
Aidoc (Israel)
PathAI, Inc. (U.S.)
Digital Diagnostics Inc. (U.S.)
Tempus AI (U.S.)
Qure.ai (U.S.)
Siemens Healthineers AG and DeepHealth, Inc. announced a strategic partnership to integrate AI-powered informatics into ultrasound workflows—marking a significant step in enabling smarter imaging hardware. This collaboration exemplifies how legacy medical technology brands are adopting AI to enhance diagnostic accuracy and streamline clinical operations.
Surge in Chronic Diseases: A rising prevalence of conditions like cancer, cardiovascular illness, and neurological disorders is pushing demand for rapid, precise diagnostic tools. For instance, breast cancer cases in the U.S. are projected to reach approximately 310,720 women and 2,800 men in 2024 alone.
Healthcare Workforce Shortages: Radiology and pathology are significantly understaffed—UK radiology staff shortages were estimated at 1,939 consultants in 2021, potentially rising to 3,600 by 2025.
Processing Big Data in Real Time: AI accelerates data interpretation and delivers early insights, especially in oncology, cardiology, and neurology—critical areas where every minute counts.
Resistance to Adoption: Some healthcare professionals hesitate to embrace AI partially due to fears of job displacement and concerns about the reliability of automated tools—posing a challenge to faster implementation.
Solutions/Software: Commanding the largest market share in 2024, this segment includes AI algorithms and analytical platforms. Ongoing collaborations between tech giants and med-tech firms continue to propel innovation.
Services: Growing steadily, this includes consulting, implementation and maintenance services—an expanding area as more healthcare providers seek to integrate AI.
Oncology: Holds the top specialty share, driven by high cancer burden and demand for early, accurate diagnosis.
Neurology, Pathology, Others: Additional segments where AI assists in early detection of neurological conditions and automates pathological assessments.
Hospitals & Clinics: Lead adoption due to integrated infrastructure and high patient throughput.
Diagnostic & Imaging Centers: Increasingly integrating AI for CT, MRI, and X-ray interpretation.
Research & Academic Institutions: Drive R&D and validation of new AI tools.
Dominates the market—valued at USD 2.65 billion in 2024—thanks to robust digital infrastructure, strong AI adoption, and home to leading vendors.
A powerhouse of innovation—with partnerships like GE Healthcare and AWS aiming to deploy generative AI in diagnostics—driving faster adoption.
On track to secure second place in regional rankings. Recently, UK’s NHS invested USD 26.8 million in AI applications to speed up CT and X-ray scans across 64 trusts.
Fastest-growing region, especially in China, Japan, and India—fuelled by rising chronic disease incidence and a lack of radiologists. In March 2025, a Hyderabad hospital implemented AI tools for the early detection of breast, lung, and pancreatic cancers.
Moderate but steady growth. In March 2025, Emirates Health Services launched AI-driven tuberculosis diagnostics at residency centers, further expanding AI reach.
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/ai-in-medical-diagnostics-market-111351
The AI in diagnostics market is far from reaching saturation. A projected CAGR of 45.4% through to 2032 suggests massive untapped potential . Key opportunity areas include:
Expansion into Under-Served Specialties: Ophthalmology, autoimmune diseases, infectious disease diagnostics remain largely untapped.
Precision Diagnostics: Investments are increasing from VCs and government bodies to build targeted AI tools .
Generative AI Models: Deep partnerships—like Microsoft & NVIDIA—are setting the stage for AI-powered imaging tools with more advanced analytics.
Broader Integration with Clinical Systems: AI being embedded into PACS, EHRs, and radiology hardware—as seen in Siemens+DeepHealth—is streamlining diagnostics workflows.
The market is semi-consolidated, with tech giants such as Microsoft, Google, and Nvidia at the forefront—backed by strategic partnerships and expansive product portfolios . Collaborations like Microsoft & Nvidia (2024) further enhance synergy between cloud, generative AI, and clinical diagnostics .
Boutique AI healthcare players—like Aidoc, PathAI, Digital Diagnostics, Tempus, and Qure.ai—are also gaining strong footholds through specialized, AI-focused offerings .
The AI in Diagnostics market is set to redefine global healthcare delivery. From cost reduction to early disease detection and remote diagnostics, the shift is monumental. Reaching USD 96.5 billion by 2032—with an impressive CAGR of 45%—this is not just technology evolution—it’s a paradigm shift. Bolstered by innovation, investment, and integration, AI-enabled diagnostics will soon become standard practice—ushering in a future of smarter, faster, and more accessible healthcare for all.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com